- Home
- YSXT vs KPTI Comparison
YSXT vs KPTI Comparison
Compare YSXT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSXT | KPTI |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | China | United States |
| Employees | 39 | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 94.6M |
| IPO Year | 2024 | 2013 |
Fundamental Metrics
Financial Performance| Metric | YSXT | KPTI |
|---|---|---|
| Price | $1.33 | $6.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $22.17 |
| AVG Volume (30 Days) | ★ 1.0M | 177.0K |
| Earning Date | 07-31-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | $71,452,736.00 | ★ $142,530,000.00 |
| Revenue This Year | N/A | $3.82 |
| Revenue Next Year | N/A | $3.18 |
| P/E Ratio | $8.52 | ★ N/A |
| Revenue Growth | ★ 22.04 | N/A |
| 52 Week Low | $1.25 | $3.51 |
| 52 Week High | $9.96 | $12.45 |
Technical Indicators
Market Signals| Indicator | YSXT | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 30.55 | 50.20 |
| Support Level | $1.25 | $5.70 |
| Resistance Level | $1.80 | $7.48 |
| Average True Range (ATR) | 0.33 | 0.49 |
| MACD | -0.06 | 0.06 |
| Stochastic Oscillator | 10.83 | 35.78 |
Price Performance
Historical ComparisonAbout YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.